COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands

1
COPD Therapeutics in Major Developed Markets to
2021 - Emergence of Addition-in-Class and
First-in-Class Products Offsets Sales Erosion of
Leading Brands
2
Report Description
COPD Therapeutics in Major Developed Markets to
2021 - Emergence of Addition-in-Class and
First-in-Class Products Offsets Sales Erosion of
Leading Brands Summary Chronic Obstructive
Pulmonary Disease (COPD) is a progressive
disorder associated with chronic inflammation of
the airways and lungs. Persistent breathing
difficulties and repeated exacerbations of COPD
symptoms make the disease one of the leading
causes of morbidity, and the fifth-leading cause
of death in the world. COPD is linked to
cumulative exposure to risk factors, primarily
tobacco smoke, but also environmental pollutants.
The COPD marketed products landscape consists of
pharmacological therapies aimed at managing the
symptoms associated with COPD, although none of
the available therapies have been shown to modify
long-term disease progression. Get complete
Report _at_ http//www.bigmarketresearch.com/copd-th
erapeutics-in-major-developed-to-2021-emergence-of
-addition-in-class-and-first-in-class-products-off
sets-sales-erosion-of-leading-brands-market
3
Report Description
There are currently 203 products in active
development, excluding four with an unknown stage
of development. Although many of the targets
identified in the pipeline are well established
in the management of COPD, there are some novel,
first-in-class targets. This reflects the growing
understanding of the underlying mechanisms that
characterize the disease. Enquire About this
report _at_ http//www.bigmarketresearch.com/report-e
nquiry/373731 Scope The COPD market has
benefited from notable additions over recent
years. - Which classes of drug dominate the
market? - What additional benefits have newly
approved therapies brought to market? - How do
the leading marketed therapies compare
clinically? The pipeline contains a range of
molecule types and molecular targets, including
those that are well established in COPD, and
novel, first-in-class therapies. - Which
molecular targets appear most frequently in the
pipeline? - How will the new therapies be
positioned in the treatment of COPD? - How have
selected late-stage pipeline therapies performed
in clinical trials? COPD clinical trials have an
overall attrition rate of 89.6.
4
Report Description
- What are the failure rates for individual
Phases of clinical development? - How do COPD
clinical trial characteristics, including failure
rate, duration, and size compare against
respiratory and industry averages? The COPD
market is forecast to rise from a value of 9.2
billion in 2014 to 11.2 billion in 2021, at a
CAGR of 2.9 across the eight major markets
assessed. - How much of a role will disease
prevalence and new product approvals play in
market growth? - Will generic competition have a
significant impact on the market over the
forecast period? There have been 59 licensing
deals and 41 co-development deals pertaining to
COPD products since 2006. - Which territories
show the most deal activity? - What were the
trends in deal completion by product stage of
development? - What were the conditions of the
key licensing or co-development deals to take
place in COPD?
5
Report Description
Reasons to buy This report will allow you to -
- Understand the current clinical and commercial
landscape through a comprehensive study of
disease pathogenesis, diagnosis, prognosis, and
the current treatment algorithm used in COPD. -
Assess the safety and efficacy of current
treatment options, with extensive product
profiles on prominent marketed therapies, and a
heatmap directly comparing safety and efficacy
data. - Analyze the COPD pipeline and stratify by
stage of development, molecule type, and
molecular target. The most promising late-stage
therapies are profiled and assessed in terms of
clinical performance and competitiveness,
alongside a single-product forecast. - Predict
growth in market size in eight major markets,
with in-depth market forecasting from 2014 to
2021. The forecasts will provide an understanding
of how epidemiology trends, new drug entries, and
patent expirations will influence market value. -
Identify commercial opportunities in the COPD
deals landscape by analyzing trends in licensing
and co-development deals, and by profiling the
most significant deals that have occurred in this
indication in recent years.
6
Table of Contents
1 Table of Contents 1 Table of Contents 2
Introduction 3 Marketed Products 4 COPD
Pipeline 5 Market Forecast to 2021 6 Deals and
Strategic Consolidations 7 Appendix
7
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/copd-therapeutics
-in-major-developed-to-2021-emergence-of-addition-
in-class-and-first-in-class-products-offsets-sales
-erosion-of-leading-brands-market
Stay With Us
TELEPHONE [phone] EMAIL
help_at_bigmarketresearch.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States